Macrocyclic Kinase Inhibitors for Selective TRK Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors for the tropomyosin receptor kinase (Trk) family are non-selective and have limitations in effectively treating pain, cancer, inflammation, and neurodegenerative diseases, with a need for more targeted and effective therapies.
Innovation Solution
Development of macrocyclic kinase inhibitors, specifically compounds represented by Formula I, II, and III, which selectively target Trk kinases, offering potent TRK inhibitory activity and significant inhibitory effects on TRKA-mutant cell growth and in vivo tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective small molecule inhibitors of TrkA, TrkB, and TrkC are used, then tumor growth inhibition and metastasis termination are achieved, but selectivity and targeted therapy effectiveness are reduced
Solution Approach 1:
The patent applies local quality by designing the macrocyclic inhibitor to specifically recognize and bind to unique structural features of TrkA, TrkB, and TrkC kinases. The macrocyclic structure contains specific functional groups and spatial arrangements that interact with disease-associated mutant forms of Trk, providing selective inhibition while maintaining broad coverage across different Trk family members and their variants.
Solution Approach 2:
The invention employs composite material principles by creating a macrocyclic molecule that integrates multiple pharmacophoric elements within a single cyclic framework. This composite structure combines hydrophobic regions for binding pocket interaction, hydrogen bonding capabilities for specific residue recognition, and steric features that discriminate between wild-type and mutant Trk kinases, achieving both selectivity and potency.
2Adaptability or versatility
If macrocyclic kinase inhibitors are developed to selectively target Trk kinases, then selectivity and targeted therapy are improved, but complexity of compound structure increases
Solution Approach 1:
The macrocyclic inhibitor is designed by segmenting the Trk kinase binding interface into distinct interaction zones within the cyclic structure. Each segment of the macrocycle targets specific regions of the kinase domain, allowing the complex structure to be rationally constructed from modular components that each contribute to selectivity for particular Trk variants.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying key structural parameters of the macrocyclic framework, including ring size, number and position of substituents, stereochemistry, and linker flexibility. These parameter optimizations balance the need for high selectivity with considerations for synthesizability and pharmacological properties, managing structural complexity through controlled variation.
Data Source
AI summary
Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.